Proud to share a new Success Story with @Lys Therapeutics, a company developing first-in-class monoclonal antibodies to treat neurodegenerative diseases like Parkinson’s.

A huge thank you to @Jordan GUYON, COO of Lys Therapeutics, for this testimonial:

“We are very satisfied in our collaboration with INITS, who have been a highly valuable partner in supporting our regulatory and quality activities over the past years.

As a biotech company developing a monoclonal antibody, we rely on strong expertise, and INITS has consistently delivered at a very high level. Their team demonstrates deep technical and regulatory knowledge, combined with a pragmatic and solution-oriented mindset.

They have supported us effectively across various topics, from documentation to regulatory interactions. Communication is clear, responsive, and professional. INITS has become a trusted extension of our team.”

#Biotech #NeurodegenerativeDiseases #Partnership #Innovation